Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges
Mateusz Hasso-Agopsowicz, Natasha S. Crowcroft, Robin Biellik, Christopher J. Gregory, Marion Menozzi-Arnaud, Jean‐Pierre Amorij, Philippe‐Alexandre Gilbert, Kristen Earle, Collrane Frivold, Courtney Jarrahian, Mercy Mvundura, Jessica Joyce Mistilis, David N Dürrheim, Birgitte Giersing
Abstract
Measles and rubella microarray patches (MR-MAPs) are critical in achieving measles and rubella eradication, a goal highly unlikely to meet with current vaccines presentations. With low commercial incentive to MAP developers, limited and uncertain funding, the need for investment in a novel manufacturing facility, and remaining questions about the source of antigen, product demand, and regulatory pathway, MR-MAPs are unlikely to be prequalified by WHO and ready for use before 2033. This article describes the current progress of MR-MAPs, highlights challenges and opportunities pertinent to MR-MAPs manufacturing, regulatory approval, creating demand, and timelines to licensure. It also describes activities that are being undertaken by multiple partners to incentivise investment in and accelerate the development of MR-MAPs.